NeurAxis, Inc. (AMEX: NRXS) is a Healthcare company (Biotechnology) with a market capitalization of $65M. The Maz Rating grades it against the other companies in its sector.
NeurAxis, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $4.61, NeurAxis, Inc. trades at 10.1x sales and 16.7x book value. Over the last twelve months it generated about $6M of revenue and a net loss of $15M. It runs a gross margin of 86.2%, an operating margin of -186.2% and a net margin of -188.2%. It shows return on equity of -252.1%, return on invested capital of -306.0% and a free cash flow yield of -9.8%. On the balance sheet: a debt-to-equity ratio of 0.10 and a current ratio of 2.10. Over the past 52 weeks the share price ranged from $2.21 to $9.33, with a beta of 1.38.
NeurAxis, Inc. does not currently pay a dividend.
1 Wall Street analyst rating covers the stock: 1 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices. Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18. NeurAxis markets its solutions to healthcare providers, predominantly hospitals and clinics. The firm, headquartered in Carmel, Indiana, was established in 2011 and operated as Innovative Health Solutions, Inc. until its rebranding to NeurAxis, Inc. in March 2022.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, NeurAxis, Inc. (NRXS) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.26% / 30% · (Cash+Inv) / Mkt Cap (36m) 5.51% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.26% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 5.51% / 33% · Receivables / Mkt Cap (36m) 1.00% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.26% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 5.51% / 33.33% · Receivables / Mkt Cap (24m) 1.00% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 1.57% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 78.1% / 33.33% · Receivables / Avg Assets (4Q) 5.73% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 3.12% / 33.33% · (Cash+ST Inv) / Total Assets 67.3% / 33.33% · (Cash+Recv) / Total Assets 79.4% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, NeurAxis, Inc. (NRXS) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. NeurAxis, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
NeurAxis, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.